Dermira Sentiment Worsening on Bad Stock Potential, Now at 0.98

Dermira, Inc. (NASDAQ:DERM) Corporate Logo

Dermira’s Sentiment

“Big money sentiment for Dermira (NASDAQ:DERM) in 2018 Q2 decreased to 0.98, according to Securities and Exchange Commission filings. That’s down -0.10, from 2018Q1’s 1.08. 53 funds opened new or increased holdings, while 54 cut down and sold positions in Dermira so the sentiment dived. Funds own 33.73 million shares, down from 34.74 million shares in 2018Q1. Funds holding Dermira in top 10 changed to 0 from 0 for the same number . 22 Investors Sold All; 32 Reduced Holdings; 32 increased holdings while 21 funds bought holdings.

Largest Dermira Investors

As of 2018 Q2 Nea Management Company Llc has 1.51% invested in Dermira. As of 2018 Q2, 1.84 million shares of Dermira are owned by Venbio Select Advisor Llc. First Midwest Bank Trust Division reported 328,170 shares. The Maryland-based fund Rock Springs Capital Management Lp have invested about 0.21% of the fund’s stock portfolio in Dermira. The Massachusetts-based fund Fernwood Investment Management Llc looks positive on Dermira, having 27,400 shares.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is valued at $458.70 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Last it reported negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

DERM is reaching $10.89 during the last trading session, after decreased 1.18%.Currently Dermira, Inc. is downtrending after 58.55% change in last December 8, 2017. DERM has also 430,384 shares volume. DERM underperformed the S&P500 by 74.17%.

On February, 28 WallStreet expected Dermira, Inc. (NASDAQ:DERM)’s earnings release, Zacks reports. Analysts expect change of 34.33 % or $0.46 from previous year’s $-1.34 EPS compared to current’s $-1.80 EPS. 13.92 % negative EPS growth is what analysts predict. $-1.58 EPS was published for last quarter.

Pnc Fincl Services Group Inc Inc holds 0% or 156 shs in its capital. Geode Capital Limited Liability Com reported 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Proshare Advisors Ltd owns 22,172 shs for 0% of their capital. Ubs Asset Americas invested 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Citadel Advsrs Ltd holds 461,497 shs or 0% of its capital. Price T Rowe Assoc Md accumulated 34,473 shs. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 1,873 shs. The Connecticut-based Cubist Systematic Strategies Limited Liability Company has invested 0.01% in Dermira, Inc. (NASDAQ:DERM). Limited Com has invested 0.02% in Dermira, Inc. (NASDAQ:DERM). Ny State Common Retirement Fund invested in 0% or 41,019 shs. Jump Trading Ltd Co reported 10,200 shs. 24,828 were accumulated by Aperio Grp Incorporated Lc. Jpmorgan Chase Communications stated it has 144,005 shs or 0% of all its holdings. Tower Cap Limited Company (Trc) holds 0% or 809 shs in its capital. Deutsche Bancorporation Ag has invested 0% in Dermira, Inc. (NASDAQ:DERM).

Dermira, Inc. had 1 sale and 4 insider purchases since June 18, 2018. This’s net activity of $424,489. 12,150 Dermira, Inc. (NASDAQ:DERM) shs with value of $119,586 were bought by WIGGANS THOMAS G.

For more Dermira, Inc. (NASDAQ:DERM) news posted briefly go to:,,, or The titles are as follows: “Intel (INTC) Gains But Lags Market: What You Should Know – Yahoo Finance” posted on August 29, 2018, “Dermira to Present at Evercore ISI HealthCONx Conference – Nasdaq” on November 19, 2018, “Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018 – GlobeNewswire” with a publish date: October 31, 2018, “Dermira enters into credit facility with Athyrium Capital Management – Seeking Alpha” and the last “Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis – GlobeNewswire” with publication date: January 31, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.